vs
Side-by-side financial comparison of ETHZilla Corp (ETHZ) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $4.1M, roughly 1.6× ETHZilla Corp). Prelude Therapeutics Inc runs the higher net margin — -303.5% vs -5273.3%, a 4969.9% gap on every dollar of revenue.
ETHZ vs PRLD — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1M | $6.5M |
| Net Profit | $-216.7M | $-19.7M |
| Gross Margin | — | — |
| Operating Margin | -5364.6% | -314.1% |
| Net Margin | -5273.3% | -303.5% |
| Revenue YoY | — | 116.7% |
| Net Profit YoY | -25803.8% | 38.9% |
| EPS (diluted) | $-16.80 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $4.1M | $6.5M | ||
| Q3 24 | $0 | $3.0M | ||
| Q3 23 | $0 | — | ||
| Q3 22 | $-1.5K | — |
| Q3 25 | $-216.7M | $-19.7M | ||
| Q3 24 | $-836.7K | $-32.3M | ||
| Q3 23 | $-10.3M | — | ||
| Q3 22 | $-21.5M | — |
| Q3 25 | -5364.6% | -314.1% | ||
| Q3 24 | — | -1145.9% | ||
| Q3 23 | — | — | ||
| Q3 22 | 264007.3% | — |
| Q3 25 | -5273.3% | -303.5% | ||
| Q3 24 | — | -1075.7% | ||
| Q3 23 | — | — | ||
| Q3 22 | 1398891.8% | — |
| Q3 25 | $-16.80 | $-0.26 | ||
| Q3 24 | $-5.43 | $-0.43 | ||
| Q3 23 | $-24.53 | — | ||
| Q3 22 | $-10.97 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $62.1M | $55.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $445.1M | $58.5M |
| Total Assets | $1.0B | $94.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $62.1M | $55.0M | ||
| Q3 24 | — | $153.6M | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | $445.1M | $58.5M | ||
| Q3 24 | $3.7M | $156.4M | ||
| Q3 23 | $-149.3K | — | ||
| Q3 22 | $26.1M | — |
| Q3 25 | $1.0B | $94.8M | ||
| Q3 24 | $10.5M | $197.2M | ||
| Q3 23 | $5.0M | — | ||
| Q3 22 | $34.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.4M | $-19.1M |
| Free Cash FlowOCF − Capex | $-259.9M | — |
| FCF MarginFCF / Revenue | -6323.7% | — |
| Capex IntensityCapex / Revenue | 5923.8% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-16.4M | $-19.1M | ||
| Q3 24 | $-239.9K | $-27.3M | ||
| Q3 23 | $-1.8M | — | ||
| Q3 22 | $-3.6M | — |
| Q3 25 | $-259.9M | — | ||
| Q3 24 | — | $-27.4M | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | -6323.7% | — | ||
| Q3 24 | — | -912.0% | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | 5923.8% | 0.0% | ||
| Q3 24 | — | 2.1% | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
